GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (OTCPK:JWCTF) » Definitions » Net Margin %

JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Net Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is JW (Cayman) Therapeutics Co Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. JW (Cayman) Therapeutics Co's Net Income for the six months ended in Dec. 2023 was $0.00 Mil. JW (Cayman) Therapeutics Co's Revenue for the six months ended in Dec. 2023 was $0.00 Mil. Therefore, JW (Cayman) Therapeutics Co's net margin for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for JW (Cayman) Therapeutics Co's Net Margin % or its related term are showing as below:

JWCTF' s Net Margin % Range Over the Past 10 Years
Min: -2280.5   Med: -580.73   Max: -441.74
Current: -476.65


JWCTF's Net Margin % is ranked worse than
64.28% of 1033 companies
in the Biotechnology industry
Industry Median: -162.58 vs JWCTF: -476.65

JW (Cayman) Therapeutics Co Net Margin % Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co Net Margin % Chart

JW (Cayman) Therapeutics Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial - - -2,280.62 -580.73 -441.74

JW (Cayman) Therapeutics Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -1,369.14 -650.31 -523.10 -433.56 -

Competitive Comparison of JW (Cayman) Therapeutics Co's Net Margin %

For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


JW (Cayman) Therapeutics Co's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's Net Margin % distribution charts can be found below:

* The bar in red indicates where JW (Cayman) Therapeutics Co's Net Margin % falls into.



JW (Cayman) Therapeutics Co Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

JW (Cayman) Therapeutics Co's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-107.559/24.349
=-441.74 %

JW (Cayman) Therapeutics Co's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=0/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


JW (Cayman) Therapeutics Co  (OTCPK:JWCTF) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


JW (Cayman) Therapeutics Co Net Margin % Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Business Description

Traded in Other Exchanges
Address
No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.

JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Headlines

No Headlines